Principal Financial Group Inc Ionis Pharmaceuticals Inc Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

A detailed history of Principal Financial Group Inc transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 13,112 shares of IONS stock, worth $450,266. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,112

Previous 17,458 24.89%

Holding current value

$450,266

Previous $832,000 36.9%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$40.06 - $51.86 $174,100 - $225,383	-4,346 Reduced 24.89%	13,112 $525,000
Q2 2024 Jul 29, 2024	SELL	$36.45 - $47.7 $450,740 - $589,858	-12,366 Reduced 41.46%	17,458 $832,000
Q1 2024 Apr 29, 2024	SELL	$42.03 - $53.55 $55,269 - $70,418	-1,315 Reduced 4.22%	29,824 $1.29 Million
Q4 2023 Feb 07, 2024	SELL	$43.39 - $51.63 $152,385 - $181,324	-3,512 Reduced 10.14%	31,139 $1.58 Million
Q3 2023 Nov 02, 2023	BUY	$38.5 - $47.13 $53,168 - $65,086	1,381 Added 4.15%	34,651 $1.57 Million
Q2 2023 Aug 07, 2023	SELL	$34.73 - $43.33 $48,483 - $60,488	-1,396 Reduced 4.03%	33,270 $1.37 Million
Q1 2023 May 09, 2023	SELL	$33.58 - $41.2 $122,768 - $150,627	-3,656 Reduced 9.54%	34,666 $1.24 Million
Q4 2022 Feb 09, 2023	SELL	$37.12 - $46.52 $814,672 - $1.02 Million	-21,947 Reduced 36.42%	38,322 $1.45 Million
Q3 2022 Nov 09, 2022	SELL	$36.54 - $48.66 $1.9 Million - $2.53 Million	-51,899 Reduced 46.27%	60,269 $2.67 Million
Q2 2022 Aug 10, 2022	BUY	$31.71 - $43.0 $2.6 Million - $3.52 Million	81,957 Added 271.28%	112,168 $4.15 Million
Q1 2022 May 09, 2022	SELL	$29.88 - $37.04 $46,134 - $57,189	-1,544 Reduced 4.86%	30,211 $1.12 Million
Q4 2021 Feb 09, 2022	SELL	$25.61 - $35.1 $279,917 - $383,643	-10,930 Reduced 25.61%	31,755 $966,000
Q3 2021 Nov 09, 2021	SELL	$33.54 - $40.55 $177,258 - $214,306	-5,285 Reduced 11.02%	42,685 $1.43 Million
Q2 2021 Aug 10, 2021	BUY	$34.54 - $47.25 $122,927 - $168,162	3,559 Added 8.01%	47,970 $1.91 Million
Q1 2021 May 10, 2021	BUY	$42.51 - $63.78 $143,896 - $215,895	3,385 Added 8.25%	44,411 $2 Million
Q4 2020 Feb 08, 2021	SELL	$45.3 - $60.27 $78,504 - $104,447	-1,733 Reduced 4.05%	41,026 $2.32 Million
Q3 2020 Nov 06, 2020	SELL	$47.45 - $62.95 $128,874 - $170,972	-2,716 Reduced 5.97%	42,759 $2.03 Million
Q2 2020 Aug 05, 2020	BUY	$46.85 - $61.05 $411,015 - $535,591	8,773 Added 23.9%	45,475 $2.68 Million
Q1 2020 May 12, 2020	BUY	$41.6 - $63.4 $51,750 - $78,869	1,244 Added 3.51%	36,702 $1.74 Million
Q4 2019 Feb 05, 2020	SELL	$53.85 - $65.27 $25,040 - $30,350	-465 Reduced 1.29%	35,458 $2.14 Million
Q3 2019 Nov 13, 2019	SELL	$59.06 - $72.15 $86,109 - $105,194	-1,458 Reduced 3.9%	35,923 $2.15 Million
Q2 2019 Aug 12, 2019	BUY	$62.09 - $86.14 $57,619 - $79,937	928 Added 2.55%	37,381 $2.4 Million
Q1 2019 May 10, 2019	BUY	$52.92 - $81.17 $169,979 - $260,718	3,212 Added 9.66%	36,453 $2.96 Million
Q4 2018 Feb 14, 2019	SELL	$43.37 - $59.54 $159,037 - $218,333	-3,667 Reduced 9.94%	33,241 $1.8 Million
Q3 2018 Nov 14, 2018	BUY	$42.88 - $53.7 $62,304 - $78,026	1,453 Added 4.1%	36,908 $1.9 Million
Q2 2018 Aug 13, 2018	SELL	$40.53 - $50.7 $114,375 - $143,075	-2,822 Reduced 7.37%	35,455 $0
Q1 2018 May 14, 2018	BUY	$44.08 - $55.05 $65,194 - $81,418	1,479 Added 4.02%	38,277 $1.69 Million
Q4 2017 Feb 13, 2018	BUY	$50.3 - $64.39 $993,626 - $1.27 Million	19,754 Added 115.9%	36,798 $1.85 Million
Q3 2017 Nov 02, 2017	BUY	$45.56 - $59.57 $776,524 - $1.02 Million	17,044	17,044 $864,000

Others Institutions Holding IONS

# of Institutions

403

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.87B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Ionis Pharmaceuticals Inc Transaction History